Nanomosaic and BMS Collaborate on White Paper to Enhance AAV Production Using Nanoneedle Technology
Nanomosaic, a leader in multiplex, multi-omic marker analysis, has announced the publication of a scientific white paper based on a study conducted in collaboration with Bristol Myers Squibb (BMS). This white paper explores the promising role of nanoneedle technology as a groundbreaking tool aimed at enhancing the understanding and quality of adeno-associated virus (AAV) manufacturing processes.
During the production of AAV, natural fluctuations in the viral genome often result in the creation of subpopulations within a single production batch. Such variations can adversely impact the efficiency and effectiveness of the therapeutic vector, potentially leading to diminished therapeutic efficacy or even unintended side effects due to the presence of suboptimal AAV subpopulations. In order to address these challenges, AAV manufacturers typically implement strategies designed to enrich preparations with particles that possess a complete transgene essential for delivering the intended therapeutic benefits.
The research highlighted in the new white paper underscores how nanoneedle technology offers a unique capability for quantitative analysis of viral genome subpopulations. This technology enables researchers to simultaneously measure titers of complete viral genomes alongside a variety of incomplete or partial species. "The nanoneedle technology serves as a valuable tool for advancing process optimization by accurately distinguishing among various particle sub-species and helping to gain a clearer understanding of manufacturing performance and product quality," notes Daniel Hurwit, Senior Principal Scientist at BMS.
One of the key findings of the study is that nanoneedle technology is able to effectively quantify AAV subpopulations, revealing critical insights into the production of full-length vectors. It also highlights the identification of pools of partial genomes that could persist in AAV feed streams, addressing significant limitations encountered with traditional methods like ITR-based titration, which have a propensity to misrepresent the true viral genome content.
The study demonstrates that with just a 2 µL sample, this high-throughput and scalable assay can be applied across various matrices, ranging from crude lysates to purified vectors, thereby enabling more accurate monitoring and optimization throughout the AAV manufacturing process. According to Qimin Quan, PhD, co-founder and Chief Scientific Officer of Nanomosaic, this innovative approach paves the way for enhanced production methodologies within the field of gene therapy.
For those interested in gaining deeper insights, the full white paper can be accessed and downloaded from the Nanomosaic website.
Bristol Myers Squibb is a global biopharmaceutical organization committed to discovering, developing, and delivering cutting-edge medicines that help patients tackle serious diseases. More information is available on their official website, BMS.com, or via their social media platforms including LinkedIn, Twitter, YouTube, Facebook, and Instagram.
Nanomosaic is at the forefront of biotechnology innovation, specializing in the development of advanced tools and technologies for multiomic biomarker detection and analysis. Their flagship product, the NanoMosaic Tessie™ System, is engineered for high-throughput biomarker detection that allows researchers to analyze multiple samples concurrently with exceptional accuracy across proteins and nucleic acids. Designed specifically for the advancement of cell and gene therapy, the platform supports the discovery and development of biomarkers across various applications, including disease diagnosis and drug development. For additional information about their offerings, please visit the Nanomosaic website.
During the production of AAV, natural fluctuations in the viral genome often result in the creation of subpopulations within a single production batch. Such variations can adversely impact the efficiency and effectiveness of the therapeutic vector, potentially leading to diminished therapeutic efficacy or even unintended side effects due to the presence of suboptimal AAV subpopulations. In order to address these challenges, AAV manufacturers typically implement strategies designed to enrich preparations with particles that possess a complete transgene essential for delivering the intended therapeutic benefits.
The research highlighted in the new white paper underscores how nanoneedle technology offers a unique capability for quantitative analysis of viral genome subpopulations. This technology enables researchers to simultaneously measure titers of complete viral genomes alongside a variety of incomplete or partial species. "The nanoneedle technology serves as a valuable tool for advancing process optimization by accurately distinguishing among various particle sub-species and helping to gain a clearer understanding of manufacturing performance and product quality," notes Daniel Hurwit, Senior Principal Scientist at BMS.
One of the key findings of the study is that nanoneedle technology is able to effectively quantify AAV subpopulations, revealing critical insights into the production of full-length vectors. It also highlights the identification of pools of partial genomes that could persist in AAV feed streams, addressing significant limitations encountered with traditional methods like ITR-based titration, which have a propensity to misrepresent the true viral genome content.
The study demonstrates that with just a 2 µL sample, this high-throughput and scalable assay can be applied across various matrices, ranging from crude lysates to purified vectors, thereby enabling more accurate monitoring and optimization throughout the AAV manufacturing process. According to Qimin Quan, PhD, co-founder and Chief Scientific Officer of Nanomosaic, this innovative approach paves the way for enhanced production methodologies within the field of gene therapy.
For those interested in gaining deeper insights, the full white paper can be accessed and downloaded from the Nanomosaic website.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical organization committed to discovering, developing, and delivering cutting-edge medicines that help patients tackle serious diseases. More information is available on their official website, BMS.com, or via their social media platforms including LinkedIn, Twitter, YouTube, Facebook, and Instagram.
About Nanomosaic
Nanomosaic is at the forefront of biotechnology innovation, specializing in the development of advanced tools and technologies for multiomic biomarker detection and analysis. Their flagship product, the NanoMosaic Tessie™ System, is engineered for high-throughput biomarker detection that allows researchers to analyze multiple samples concurrently with exceptional accuracy across proteins and nucleic acids. Designed specifically for the advancement of cell and gene therapy, the platform supports the discovery and development of biomarkers across various applications, including disease diagnosis and drug development. For additional information about their offerings, please visit the Nanomosaic website.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.